The GenomeLab SNPstream Genotyping System is capable of performing 4,600 to over 3 Million genotypes per day. Part of the GenomeLab family of products*, this automated, scalable, multiplexed system can process up to 48 SNPs in each well of an arrayed 384-well plate, for cost-effective high throughput SNP analysis. Based on single-based primer extension reaction technology, the system integrates hardware, software and reagents in a compact design. SNPstream users can also access Beckman Coulters Autoprimer.com, a unique web-based tool that automatically provides primers and tag assignments in a matter of seconds, using proprietary algorithms.

GenomeLab SNPstream Genotyping Systems feature a simple protocol with just three steps, compared to over 15 steps that are required for competitive systems. Based on single-based primer extension technology, the 48-plex SNPstream system operates at 99% accuracy. The systems high sensitivity delivers accurate results using as little as 2 ng of genomic DNA. The plates are compatible with Biomek series liquid handlers, for fast pre-and post-PCR* setup.

All components of the SNPstream system are provided by Beckman Coulter and are optimized for seamless genotyping. The system operates at a consistent cost per genotype or per sample, regardless of run throughput, allowing users to cost-effectively zero in on targets with low-throughput studies as well as conduct high-throughput analyses.

The SNPstream system includes a CCD-based imager, data analysis workstation, integrated bar code reader, automatic robotic plate handler and software and reagents. The software suite is a comprehensive set of advanced, easy-to-use tools for the complete workflow process, from primer design to 384-well plate setup, image data analysis and genotype calling.

*GenomeLab is a family of genetic analysis tools from Beckman Coulter that innovate, simplify and automate genomics processes to enable identification of new markers of biological, diagnostic and therapeutic interest. GenomeLab solutions help researchers identify the differences between normal and diseased states, isolate and purify samples, prepare nucleic acids, analyze and evaluate genetic material. GenomeLab tools will be used in the validation of biomarkers and their association with specific disease states as well as in the evaluation of drug efficacy, and may lead to a new generation of standardized diagnostic tests with the promise of delivering personalized medicine.